Autopsy report · NCT00880048
A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder
Cause of deathOther
“To allow assessment of isolated events of seizure during program”
Life of this trial
- Ran for about 1 year 3 months before it stopped.
- 343 participants enrolled.
- Results were posted on the registry 7 years 4 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- GlaxoSmithKline
- Sponsor type
- Industry
- Conditions
- Depressive Disorder
- Interventions
- orvepitant; Placebo
- Participants
- 343
- Sites
- 32
- Countries
- Canada, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.